Relapsed/Refractory Marginal Zone Lymphoma (MZL) Clinical Trials

4 clinical trials for Relapsed/Refractory Marginal Zone Lymphoma (MZL) across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma — RECRUITING · PHASE3
• A Study of APG-3288 in Relapsed/Refractory Blood Cancers — RECRUITING · PHASE1
• Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma — RECRUITING · PHASE3
• An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma — TERMINATED · PHASE2

Refine this search